Source:http://linkedlifedata.com/resource/pubmed/id/20412867
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2010-9-6
|
| pubmed:abstractText |
The incidence of excessive adiposity is increasing worldwide, and is associated with numerous adverse health outcomes. We compared outcomes by body mass index (BMI) for adult patients with acute myelogenous leukemia (AML) who underwent autologous (auto, n = 373), related donor (RD, n = 2041), or unrelated donor (URD, n = 1801) allogeneic myeloablative hematopoietic cell transplantation (HCT) using bone marrow or peripheral blood stem cells reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) from 1995 to 2004. Four weight groups by BMI (kg/m(2)) were defined: underweight <18 kg/m(2); normal 18-25 kg/m(2); overweight >25-30 kg/m(2); and obese >30 kg/m(2). Multivariable analysis referenced to the normal weight group showed an increased risk of death for underweight patients in the RD group (relative risk [RR], 1.92; 95% confidence interval [CI], 1.28-2.89; P = .002), but not in the URD group. There were no other differences in outcomes among the other weight groups within the other HCT groups. Overweight and obese patients enjoyed a modest decrease in relapse incidence, although this did not translate into a survival benefit. Small numbers of patients limit the ability to better characterize the adverse outcomes seen in the underweight RD but not the underweight URD allogeneic HCT patients. Obesity alone should not be considered a barrier to HCT.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
1523-6536
|
| pubmed:author |
pubmed-author:AgoviManza-AMA,
pubmed-author:BallenKarenK,
pubmed-author:BolwellBrian JBJ,
pubmed-author:FrangoulHaydarH,
pubmed-author:GuptaVikasV,
pubmed-author:HahnTheresaT,
pubmed-author:HoVincent TVT,
pubmed-author:JuckettMarkM,
pubmed-author:LazarusHillard MHM,
pubmed-author:LiesveldJane LJL,
pubmed-author:LitzowMark RMR,
pubmed-author:LoganBrent RBR,
pubmed-author:MarksDavid IDI,
pubmed-author:McCarthyPhilip LPL,
pubmed-author:MorebJan SJS,
pubmed-author:NavarroWillis HWH,
pubmed-author:PasquiniMarcelo CMC,
pubmed-author:RizzoJ DouglasJD
|
| pubmed:copyrightInfo |
Copyright © 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
16
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1442-50
|
| pubmed:dateRevised |
2011-10-3
|
| pubmed:meshHeading |
pubmed-meshheading:20412867-Acute Disease,
pubmed-meshheading:20412867-Adolescent,
pubmed-meshheading:20412867-Adult,
pubmed-meshheading:20412867-Aged,
pubmed-meshheading:20412867-Bone Marrow Transplantation,
pubmed-meshheading:20412867-Comorbidity,
pubmed-meshheading:20412867-Disease-Free Survival,
pubmed-meshheading:20412867-Female,
pubmed-meshheading:20412867-Graft vs Host Disease,
pubmed-meshheading:20412867-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:20412867-Humans,
pubmed-meshheading:20412867-Kaplan-Meier Estimate,
pubmed-meshheading:20412867-Leukemia, Myeloid,
pubmed-meshheading:20412867-Male,
pubmed-meshheading:20412867-Middle Aged,
pubmed-meshheading:20412867-Myeloablative Agonists,
pubmed-meshheading:20412867-Obesity,
pubmed-meshheading:20412867-Overweight,
pubmed-meshheading:20412867-Prognosis,
pubmed-meshheading:20412867-Retrospective Studies,
pubmed-meshheading:20412867-Thinness,
pubmed-meshheading:20412867-Transplantation, Homologous,
pubmed-meshheading:20412867-Transplantation Conditioning,
pubmed-meshheading:20412867-Treatment Outcome,
pubmed-meshheading:20412867-Young Adult
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults.
|
| pubmed:affiliation |
National Marrow Donor Program, Minneapolis, Minnesota 55413, USA. wnavarro@nmdp.org
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Research Support, N.I.H., Extramural
|